Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Neurology

Clinical Trials

Pharmaceutical

Biotechnology

Next Generation Treatments for Parkinson’s and Alzheimer’s Disease

More Like This

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Announces Corporate Restructuring

Prothena to Participate in Upcoming Healthcare Conferences

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration